Amendments to the Specification:

Please amend the paragraph at page 17, lines 5-32 as follows.

Peptides particularly of interest for use in the present invention include laminin, which has the sequence

YIGSR

(SEQ ID NO: 7)

echistatin, which has the sequence

ECESGPCCRNCKFLKEGTICKRARGDDMDDYCNGKTCDCPRNPHKGPAT

(SEQ ID NO: 8)

RGD, NGR and derivatives thereof having the sequences

$RX_1ETX_2WX_3$

(SEQ ID NO: 9)

wherein X_1, X_2, and X_3 are any amino acid;

$CX_1X_2RLDX_3X_4C$

(SEQ ID NO: 11)

wherein X_1, X_2, X_3 and X_4 are any amino acid;

$X_1X_2X_3RGDX_4X_5X_6$

(SEQ ID NO: 13)

wherein X_1, X_3, X_4, and X_6 are capable of forming a bridge (by disulfide bonds, peptide bonds or lactam bonds) and X_2 and X_5 are 1 to 5 amino acids;

$CX_2CRGDCX_5C$

(SEQ ID NO: 14)

wherein X_2 and X_5 are 1 to 5 amino acids;

$X_1X_2DDX_4X_5X_7X_8$

~~(SEQ ID NO: 15)~~

<u>and</u>

<u>$X_1X_2X_3DDX_4X_5X_6X_7X_8$</u>

<u>(SEQ ID NOS: 15, 16, 138-161)</u> ~~wherein X₁ and X₈ each is an independently selected amino acid, X₂ and X₇ together equal 0 to 4 amino acids, each amino acid of which is independently selected, X₄ is selected from the group consisting of glycine and leucine, and X₅ is selected from the group consisting of tryptophan and leucine;~~

2

$$\text{X}_1\text{X}_2\text{X}_3\text{DDX}_4\text{X}_5\text{X}_6\text{X}_7\text{X}_8$$

~~(SEQ ID NO: 16)~~

wherein X_1 and X_8 each is an independently selected amino acid, X_2 and X_7 together equal 0 to 3 amino acids, each amino acid of which is independently selected, X_3 is selected from the group consisting of tryptophan and proline, X_4 is selected from the group consisting of glycine and leucine, X_5 is selected from the group consisting of tryptophan and leucine, and X_6 is selected from the group consisting of leucine, tryptophan, and methionine. The substituents X_1, X_2, X_3, X_4, X_5, X_6, X_7, and X_8 are as defined in International applications WO 95/14714, published June 1, 1995 and WO 97/08203, published March 6, 1997 (corresponding to U.S. Pat. Nos. 5,627,263 and 5,817,750, respectively), which are incorporated by reference in their entirety.

Please change the paragraph at page 42, line 26 to page 43, line 6 as follows:

The inventors contemplate preferred molecules having different peptide sequences attached to a vehicle. For example, a preferred molecule may include the sequences

$$\text{F}^1\text{-}\Lambda\text{-YIGSR-}\Lambda\text{-RGD}$$

~~(SEQ ID NO: 95)~~

$$\text{YIGSR-}\Lambda\text{–RGD-}\Lambda\text{-F}^1$$

~~(SEQ ID NO: 96)~~

wherein "F^1" is an Fc domain as described previously herein and "Λ" is a linker as described previously herein.

Please change Table 6, page 21, as follows:

Table 6—Laminin-related peptide sequences

Sequence/structure	SEQ ID NO:
YIGSRYIGSR [i.e., (YIGSR)$_2$]	128
YIGSRYIGSRYIGSR [i.e., (YIGSR)$_3$]	129
YIGSRYIGSRYIGSRYIGSR [i.e., (YIGSR)$_4$]	130
YIGSRYIGSRYIGSRYIGSRYIGSR [i.e., (YIGSR)$_5$]	131
IPCNNKGAHSVGLMWWMLAR	132
YIGSRREDVEILDVPDSGR	133
RGDRGDYIGSRRGD	134
YIGSRYIGSRYIGSRYIGSR	135
REDVEILDVYIGSRPDSGR	~~136~~ 95
YIGSRREDVEILDVPDSGR	~~137~~ 96